Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s43018-021-00177-w
PubMed Identifier: 35121960
Publication URI: http://europepmc.org/abstract/MED/35121960
Type: Journal Article/Review
Volume: 2
Parent Publication: Nature cancer
Issue: 3
ISSN: 2662-1347